CDK8 and postmenopausal osteoporosis: Our findings demonstrated that the CDK8-STAT1-RANKL axis in MSCs could play a crucial role in maintaining bone resorption and homeostasis, indicating that targeting MSCs through CDK8 inhibition could be a promising strategy against various metabolic bone diseases associated with abnormal osteoclastogenesis, including age-related osteoporosis and postmenopausal osteoporosis.